Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous

Annie Drapeau, David Fortin1

  • 1Department of surgery, Division of neurosurgery and neuro-oncology, CHUS, Université de Sherbrooke, 3001, 12th Avenue North, Sherbrooke, Quebec, Canada, J1H 5N4. David.Fortin@USherbrooke.ca.

Insights

Malignant brain tumors are difficult to treat due to the blood-brain barrier (BBB) and blood-tumor barrier (BTB). This review explores advanced delivery strategies to improve drug access for better patient outcomes.

Area of Science:

  • Neuro-oncology
  • Drug Delivery Systems
  • Biomedical Engineering

Background:

  • Malignant brain tumors, including glioblastoma multiforme and metastases, present significant therapeutic challenges.
  • Current treatments (surgery, radiotherapy, chemotherapy) offer limited survival benefits.
  • The blood-brain barrier (BBB) and blood-tumor barrier (BTB) impede effective drug delivery to the central nervous system.

Purpose of the Study:

  • To review the critical role of the BBB and BTB in brain tumor treatment.
  • To evaluate various advanced drug delivery strategies for malignant brain tumors.
  • To discuss the current status and future potential of these delivery methods.

Main Methods:

  • Review of existing literature on drug delivery techniques for brain tumors.
  • Analysis of surgical and physical methods to enhance drug distribution.
  • Discussion of specific strategies including intra-arterial delivery, osmotic BBB disruption, intranasal delivery, convection-enhanced delivery, osmotic pumps, implanted polymers, magnetic microspheres, and ultrasound BBB disruption.

Main Results:

  • The BBB and BTB pose significant hurdles to effective chemotherapy.
  • Several innovative delivery strategies show promise in overcoming these barriers.
  • Optimizing drug delivery is crucial for improving patient outcomes in neuro-oncology.

Conclusions:

  • Advanced drug delivery strategies are essential for improving the efficacy of malignant brain tumor treatments.
  • Further research and clinical application of these methods are needed to overcome the limitations of conventional therapies.
  • Targeted delivery systems offer a promising future for neuro-oncology patients.

Related Concept Videos

Drug Delivery: Parenteral Route01:29

Drug Delivery: Parenteral Route

The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
2.7K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
773
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
1.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.7K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
879